Please use this identifier to cite or link to this item:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/17784Full metadata record
| ???org.dspace.app.webui.jsptag.ItemTag.dcfield??? | Value | Language |
|---|---|---|
| dc.contributor.advisor | 郭彥彬(Yen-Ping Kuo) | |
| dc.contributor.author | Yue-Ju Li | en |
| dc.contributor.author | 李月如 | zh_TW |
| dc.date.accessioned | 2021-06-08T00:43:31Z | - |
| dc.date.available | 2030-01-01 | - |
| dc.date.copyright | 2015-09-24 | |
| dc.date.issued | 2015 | |
| dc.date.submitted | 2015-08-12 | |
| dc.identifier.citation | 1. Heierhorst J. Mdt1/ASCIZ: a new DNA damage response protein family. Cell Cycle 2008;7:2654-60. 2. McNees CJ, Conlan LA, Tenis N, et al. ASCIZ regulates lesion-specific Rad51 focus formation and apoptosis after methylating DNA damage. EMBO J 2005;24:2447-57. 3. Jurado S, Smyth I, van Denderen B, et al. Dual functions of ASCIZ in the DNA base damage response and pulmonary organogenesis. PLoS Genet 2010;6:e1001170. 4. Kanu N, Penicud K, Hristova M, et al. The ATM cofactor ATMIN protects against oxidative stress and accumulation of DNA damage in the aging brain. J Biol Chem 2010;285:38534-42. 5. Kanu N, Behrens A. ATMIN defines an NBS1-independent pathway of ATM signalling. EMBO J 2007;26:2933-41. 6. Loizou JI, Sancho R, Kanu N, et al. ATMIN is required for maintenance of genomic stability and suppression of B cell lymphoma. Cancer Cell 2011;19:587-600. 7. Liu X, Zha S. ATMIN: a new tumor suppressor in developing B cells. Cancer Cell 2011;19:569-70. 8. Jurado S, Gleeson K, O'Donnell K, et al. The Zinc-finger protein ASCIZ regulates B cell development via DYNLL1 and Bim. J Exp Med 2012;209:1629-39. 9. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70. 10. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74. 11. Klymkowsky MW, Savagner P. Epithelial-mesenchymal transition: a cancer researcher's conceptual friend and foe. Am J Pathol 2009;174:1588-93. 12. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009;9:265-73. 13. Thiery JP, Acloque H, Huang RY, et al. Epithelial-mesenchymal transitions in development and disease. Cell 2009;139:871-90. 14. Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 2009;28:15-33. 15. Barrallo-Gimeno A, Nieto MA. The Snail genes as inducers of cell movement and survival: implications in development and cancer. Development 2005;132:3151-61. 16. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007;26:1324-37. 17. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature 2004;432:307-15. 18. Junttila MR, Evan GI. p53--a Jack of all trades but master of none. Nat Rev Cancer 2009;9:821-9. 19. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001;411:366-74. 20. Hoeijmakers JH. DNA damage, aging, and cancer. N Engl J Med 2009;361:1475-85. 21. Frebourg T, Friend SH. Cancer risks from germline p53 mutations. J Clin Invest 1992;90:1637-41. 22. Lavin MF, Shiloh Y. The genetic defect in ataxia-telangiectasia. Annu Rev Immunol 1997;15:177-202. 23. Lehmann AR. DNA repair-deficient diseases, xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy. Biochimie 2003;85:1101-11. 24. O'Driscoll M, Ruiz-Perez VL, Woods CG, et al. A splicing mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome. Nat Genet 2003;33:497-501. 25. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 2003;3:155-68. 26. Taylor AM, Groom A, Byrd PJ. Ataxia-telangiectasia-like disorder (ATLD)-its clinical presentation and molecular basis. DNA Repair (Amst) 2004;3:1219-25. 27. Nevanlinna H, Bartek J. The CHEK2 gene and inherited breast cancer susceptibility. Oncogene 2006;25:5912-9. 28. Fackenthal JD, Olopade OI. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 2007;7:937-48. 29. Meindl A, Hellebrand H, Wiek C, et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 2010;42:410-4. 30. Loeb LA, Loeb KR, Anderson JP. Multiple mutations and cancer. Proc Natl Acad Sci U S A 2003;100:776-81. 31. Jiricny J. The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol 2006;7:335-46. 32. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature 2009;461:1071-8. 33. Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature 2012;481:287-94. 34. Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med 2008;359:1143-54. 35. Yang CN, Deng YT, Tang JY, et al. MicroRNA-29b regulates migration in oral squamous cell carcinoma and its clinical significance. Oral Oncol 2015;51:170-7. 36. Wutzl A, Ploder O, Kermer C, et al. Mortality and causes of death after multimodality treatment for advanced oral and oropharyngeal cancer. J Oral Maxillofac Surg 2007;65:255-60. 37. Jerjes W, Upile T, Petrie A, et al. Clinicopathological parameters, recurrence, locoregional and distant metastasis in 115 T1-T2 oral squamous cell carcinoma patients. Head Neck Oncol 2010;2:9. 38. Kademani D. Oral cancer. Mayo Clin Proc 2007;82:878-87. 39. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin 2014;64:104-17. 40. Lin BR, Chang CC, Chen RJ, et al. Connective tissue growth factor acts as a therapeutic agent and predictor for peritoneal carcinomatosis of colorectal cancer. Clin Cancer Res 2011;17:3077-88. 41. Manfredi S, Bouvier AM, Lepage C, et al. Incidence and patterns of recurrence after resection for cure of colonic cancer in a well defined population. Br J Surg 2006;93:1115-22. 42. Ogino S, Goel A. Molecular classification and correlates in colorectal cancer. J Mol Diagn 2008;10:13-27. 43. Redston M. Carcinogenesis in the GI tract: from morphology to genetics and back again. Mod Pathol 2001;14:236-45. 44. Compton CC. Colorectal carcinoma: diagnostic, prognostic, and molecular features. Mod Pathol 2003;16:376-88. 45. Divaris K, Olshan AF, Smith J, et al. Oral health and risk for head and neck squamous cell carcinoma: the Carolina Head and Neck Cancer Study. Cancer Causes Control 2010;21:567-75. 46. Muwonge R, Ramadas K, Sankila R, et al. Role of tobacco smoking, chewing and alcohol drinking in the risk of oral cancer in Trivandrum, India: a nested case-control design using incident cancer cases. Oral Oncol 2008;44:446-54. 47. Manoharan S, Singh R.B, Balakrishnan S. Chemopreventive Mechanisms of Natural Products in Oral, Mammary and Skin Carcinogenesis: An Overview. The Open Nutraceuticals Journal 2009;2:52-63. 48. Gleber-Netto FO, Braakhuis BJ, Triantafyllou A, et al. Molecular events in relapsed oral squamous cell carcinoma: Recurrence vs secondary primary tumor. Oral Oncol 2015. 49. Sinha N, Mukhopadhyay S, Das DN, et al. Relevance of cancer initiating/stem cells in carcinogenesis and therapy resistance in oral cancer. Oral Oncol 2013;49:854-62. 50. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49. 51. Cheung ST, Chen X, Guan XY, et al. Identify metastasis-associated genes in hepatocellular carcinoma through clonality delineation for multinodular tumor. Cancer Res 2002;62:4711-21. 52. Soreide K, Janssen EA, Soiland H, et al. Microsatellite instability in colorectal cancer. Br J Surg 2006;93:395-406. 53. Pino MS, Chung DC. Microsatellite instability in the management of colorectal cancer. Expert Rev Gastroenterol Hepatol 2011;5:385-99. 54. Duval A, Gayet J, Zhou XP, et al. Frequent frameshift mutations of the TCF-4 gene in colorectal cancers with microsatellite instability. Cancer Res 1999;59:4213-5. 55. Fukushima H, Yamamoto H, Itoh F, et al. Frequent alterations of the beta-catenin and TCF-4 genes, but not of the APC gene, in colon cancers with high-frequency microsatellite instability. J Exp Clin Cancer Res 2001;20:553-9. 56. Saeki H, Tanaka S, Tokunaga E, et al. Genetic alterations in the human Tcf-4 gene in Japanese patients with sporadic gastrointestinal cancers with microsatellite instability. Oncology 2001;61:156-61. 57. Chang HR, Cheng TL, Liu TZ, et al. Genetic and cellular characterizations of human TCF4 with microsatellite instability in colon cancer and leukemia cell lines. Cancer Lett 2006;233:165-71. 58. Buono P, Mancini FP, Izzo P, et al. Characterization of the transcription-initiation site and of the promoter region within the 5' flanking region of the human aldolase C gene. Eur J Biochem 1990;192:805-11. 59. Kajita E, Moriwaki J, Yatsuki H, et al. Quantitative expression studies of aldolase A, B and C genes in developing embryos and adult tissues of Xenopus laevis. Mech Dev 2001;102:283-7. 60. Hatakeyama K, Ohshima K, Fukuda Y, et al. Identification of a novel protein isoform derived from cancer-related splicing variants using combined analysis of transcriptome and proteome. Proteomics 2011;11:2275-82. 61. Kim GP, Colangelo LH, Wieand HS, et al. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol 2007;25:767-72. 62. Des Guetz G, Schischmanoff O, Nicolas P, et al. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur J Cancer 2009;45:1890-6. 63. Jover R, Zapater P, Castells A, et al. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur J Cancer 2009;45:365-73. 64. Dolcetti R, Viel A, Doglioni C, et al. High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am J Pathol 1999;154:1805-13. 65. Phillips SM, Banerjea A, Feakins R, et al. Tumour-infiltrating lymphocytes in colorectal cancer with microsatellite instability are activated and cytotoxic. Br J Surg 2004;91:469-75. 66. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005;23:609-18. 67. Du C, Zhao J, Xue W, et al. Prognostic value of microsatellite instability in sporadic locally advanced rectal cancer following neoadjuvant radiotherapy. Histopathology 2013;62:723-30. 68. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986;315:1650-9. 69. Provost E, Rimm DL. Controversies at the cytoplasmic face of the cadherin-based adhesion complex. Curr Opin Cell Biol 1999;11:567-72. 70. de La Coste A, Romagnolo B, Billuart P, et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci U S A 1998;95:8847-51. 71. Korinek V, Barker N, Morin PJ, et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997;275:1784-7. 72. Satoh S, Daigo Y, Furukawa Y, et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 2000;24:245-50. 73. van Noort M, Clevers H. TCF transcription factors, mediators of Wnt-signaling in development and cancer. Dev Biol 2002;244:1-8. 74. Shtutman M, Zhurinsky J, Simcha I, et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A 1999;96:5522-7. 75. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-70. 76. Korinek V, Barker N, Moerer P, et al. Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. Nat Genet 1998;19:379-83. 77. Sato S, Idogawa M, Honda K, et al. Beta-catenin interacts with the FUS proto-oncogene product and regulates pre-mRNA splicing. Gastroenterology 2005;129:1225-36. 78. Idogawa M, Yamada T, Honda K, et al. Poly(ADP-ribose) polymerase-1 is a component of the oncogenic T-cell factor-4/beta-catenin complex. Gastroenterology 2005;128:1919-36. 79. Idogawa M, Masutani M, Shitashige M, et al. Ku70 and poly(ADP-ribose) polymerase-1 competitively regulate beta-catenin and T-cell factor-4-mediated gene transactivation: possible linkage of DNA damage recognition and Wnt signaling. Cancer Res 2007;67:911-8. 80. Shitashige M, Naishiro Y, Idogawa M, et al. Involvement of splicing factor-1 in beta-catenin/T-cell factor-4-mediated gene transactivation and pre-mRNA splicing. Gastroenterology 2007;132:1039-54. 81. Huang L, Shitashige M, Satow R, et al. Functional interaction of DNA topoisomerase IIalpha with the beta-catenin and T-cell factor-4 complex. Gastroenterology 2007;133:1569-78. 82. Mahale A, Saranath D. Microsatellite alterations on chromosome 9 in chewing tobacco-induced oral squamous cell carcinomas from India. Oral Oncol 2000;36:199-206. 83. Penhoet EE, Rutter WJ. Catalytic and immunochemical properties of homomeric and heteromeric combinations of aldolase subunits. J Biol Chem 1971;246:318-23. 84. Haimoto H, Kato K. Highly sensitive enzyme immunoassay for human brain aldolase C. Clin Chim Acta 1986;154:203-11. 85. Hu CJ, Wang LY, Chodosh LA, et al. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol 2003;23:9361-74. 86. Jean JC, Rich CB, Joyce-Brady M. Hypoxia results in an HIF-1-dependent induction of brain-specific aldolase C in lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 2006;291:L950-6. 87. Sato S, Sugimura T, Chien TC, et al. Aldolase isozyme patterns of human brain tumors. Cancer 1971;27:223-7. 88. Schapira F, Hatzfeld A, Reuber MD. Fetal pattern of aldolase in transplantable hepatomas. Cancer Res 1971;31:1224-30. 89. Ojika T, Imaizumi M, Abe T, et al. Immunochemical and immunohistochemical studies on three aldolase isozymes in human lung cancer. Cancer 1991;67:2153-8. 90. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002;2:563-72. 91. Csibi A, Fendt SM, Li C, et al. The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell 2013;153:840-54. 92. Son J, Lyssiotis CA, Ying H, et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 2013;496:101-5. 93. Yang L, Moss T, Mangala LS, et al. Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Mol Syst Biol 2014;10:728. 94. Graham NA, Tahmasian M, Kohli B, et al. Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death. Mol Syst Biol 2012;8:589. 95. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-33. 96. Rizwan A, Serganova I, Khanin R, et al. Relationships between LDH-A, lactate, and metastases in 4T1 breast tumors. Clin Cancer Res 2013;19:5158-69. 97. Ishida A, Tada Y, Nimura T, et al. Identification of major Ca(2+)/calmodulin-dependent protein kinase phosphatase-binding proteins in brain: biochemical analysis of the interaction. Arch Biochem Biophys 2005;435:134-46. 98. Kim JH, Lee S, Kim JH, et al. Phospholipase D2 directly interacts with aldolase via Its PH domain. Biochemistry 2002;41:3414-21. 99. Kao AW, Noda Y, Johnson JH, et al. Aldolase mediates the association of F-actin with the insulin-responsive glucose transporter GLUT4. J Biol Chem 1999;274:17742-7. 100. Lundmark R, Carlsson SR. Regulated membrane recruitment of dynamin-2 mediated by sorting nexin 9. J Biol Chem 2004;279:42694-702. 101. Buscaglia CA, Penesetti D, Tao M, et al. Characterization of an aldolase-binding site in the Wiskott-Aldrich syndrome protein. J Biol Chem 2006;281:1324-31. 102. Jewett TJ, Sibley LD. Aldolase forms a bridge between cell surface adhesins and the actin cytoskeleton in apicomplexan parasites. Mol Cell 2003;11:885-94. 103. Wang J, Tolan DR, Pagliaro L. Metabolic compartmentation in living cells: structural association of aldolase. Exp Cell Res 1997;237:445-51. 104. Pagliaro L, Taylor DL. Aldolase exists in both the fluid and solid phases of cytoplasm. J Cell Biol 1988;107:981-91. 105. Pagliaro L, Taylor DL. 2-Deoxyglucose and cytochalasin D modulate aldolase mobility in living 3T3 cells. J Cell Biol 1992;118:859-63. 106. Du S, Guan Z, Hao L, et al. Fructose-bisphosphate aldolase a is a potential metastasis-associated marker of lung squamous cell carcinoma and promotes lung cell tumorigenesis and migration. PLoS One 2014;9:e85804. 107. Penhoet E, Rajkumar T, Rutter WJ. Multiple forms of fructose diphosphate aldolase in mammalian tissues. Proc Natl Acad Sci U S A 1966;56:1275-82. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/17784 | - |
| dc.description.abstract | 癌症是目前世界上非常棘手的問題，也是臨床上病人死亡的重要疾病之一。雖然它已被研究長達數十年，但是目前對它的致病機轉及治療方針瞭解並不完全。不同的癌症種類，例如：口腔癌及大腸直腸癌，甚至於不同亞型，像是大腸癌中的微星粒不穩定型(MSI)及穩定型(MSS)致病機轉及治療結果也不盡相同。在本研究中，我們透過微陣列分析出的幾個特殊基因，期望找出其在不同癌症中的調控機轉。運用高通量的分析方法偵測調控癌症轉移的可能下游影響分子，並使用即時聚合酶鏈鎖反應法分析病人檢體來確認這些基因的角色，包括：ataxia telangiectasia mutated interactor (ATMIN)，同時進一步分析其與臨床預後的關係。藉由體外細胞株給予或去除基因來評估其功能，及原位注射或脾臟注射的小鼠動物模式來觀察淋巴轉移及肝臟轉移，研究結果發現ATMIN的高表現量與口腔癌及大腸癌中微星粒穩定型的臨床期別成正比且病人預後較差，但卻與微星粒不穩定亞型的臨床期別成反比而病人預後較佳。總結來說，基因的功能仰賴不同的癌症或亞型而有不同的影響力，相信此論文提供了未來癌症個人化醫療之重要的參考證據。 | zh_TW |
| dc.description.abstract | Cancer is the serious issue worldwide and responsible for many deaths. Even though it has been studied for several decades, it is still mysterious. The different cancer types, such as oral squama cancer cell (OSCC) and colorectal cancer cell (CRC), and even the same cancer with different subtypes, such as CRC microsatellite instable (MSI) and CRC microsatellite stable (MSS), come out with different ways. In this study, we aimed to explore the roles of several genes that were identified by microarray analysis and their regulatory mechanisms in different cancer types. The high throughput analysis was used to detect the downstream effectors of target gene-regulated metastasis. The cancers specimens were detected by Quantitative RT-PCR to confirm the roles of the genes, including ataxia telangiectasia mutated interactor (ATMIN), and were analyzed with these gene expression and clinical outcomes by Kaplan–Meier analyses. The functions of ectopic genes expression or silencing on cell behavior were evaluated in vitro. Lymph node metastasis and liver metastasis abilities were investigated by orthotropic and splenic injection in animal model. Interestingly, ATMIN mRNA expression was correlated with advanced stages in OSCC and CRC/MSS, but negatively correlated with CRC/MSI population. Moreover, in vivo animal experiments were confirmed the result as clinical samples. In conclusion, the gene functions were various depending on cancer types even subtypes, it provides the strong evidence for personalize medical treatment. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-08T00:43:31Z (GMT). No. of bitstreams: 1 ntu-104-D99422004-1.pdf: 7320489 bytes, checksum: 0c56e5e2cc9fcb858b80159d574e9ae6 (MD5) Previous issue date: 2015 | en |
| dc.description.tableofcontents | Content 論文口試委員會審定書 i 中文摘要 ii Abstract iii Content v Chapter I Introduction 1 1.1 ataxia telangiectasia mutated interactor (ATMIN) 2 1.2 Cancer progression 3 1.2.1 Cancer generation 3 1.2.2 Oral squama cancer cell (OSCC) 4 1.2.3 Colorectal cancer cell (CRC) 6 Chapter II The roles of ATMIN in OSCC 10 2.1 Rational 11 2.2 Material and Method 12 2.3 Results 17 Chapter III The roles of ATMIN in CRC 20 3.1 Rational 21 3.2 Material and Method 22 3.3 Results 29 Chapter IV Discussion 38 Chapter V Conclusion 44 Chapter VI Reference 46 Chapter VII Tables, Figures and Figures legends 54 Chapter VIII Publication list 86 Chapter IX Appendix 88 | |
| dc.language.iso | en | |
| dc.title | 運動失調毛細血管擴張症突變相互作用因子在癌症進程中之角色 | zh_TW |
| dc.title | The role of ataxia telangiectasia mutated interactor in cancer progression | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 103-2 | |
| dc.description.degree | 博士 | |
| dc.contributor.coadvisor | 張正琪(Cheng-Chi Chang) | |
| dc.contributor.oralexamcommittee | 楊慕華(Muh-Hwa Yang),李心予,林本仁 | |
| dc.subject.keyword | 運動失調毛細血管擴張突變相互作用因子,醛??,微星粒不穩定亞型,微星粒穩定亞型,口腔癌,大腸直腸癌,乙型連環蛋白, | zh_TW |
| dc.subject.keyword | ATMIN,ALDOC,MSI,MSS,OSCC,CRC,beta-catenin, | en |
| dc.relation.page | 99 | |
| dc.rights.note | 未授權 | |
| dc.date.accepted | 2015-08-12 | |
| dc.contributor.author-college | 牙醫專業學院 | zh_TW |
| dc.contributor.author-dept | 臨床牙醫學研究所 | zh_TW |
| dc.date.embargo-terms | 2030-01-01 | |
| Appears in Collections: | 臨床牙醫學研究所 | |
Files in This Item:
| File | Size | Format | |
|---|---|---|---|
| ntu-104-1.pdf Restricted Access | 7.15 MB | Adobe PDF |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.